Peptavo is Accredited for 20 CME hours.Peptavo is Jointly Accredited for 20 CME hours. Learn more about accreditation
PEPTAVO
The Stack Source LLC1908 E 11th Street Austin, TX 78702support@peptavo.com(512) 827-8158DBA: Peptavo
Peptavo is Accredited for 20 CME hours.Peptavo is Jointly Accredited for 20 CME hours. Learn more about accreditation
Get volume discounts if you are getting 3 or more clinicians certified
Book a Call
Yes. Physician assistants can prescribe peptides in every state, under the same prescriptive authority that covers any prescription drug. Whether a given PA can prescribe a given peptide turns on four checks: the state's physician rules, the practice agreement, the product's legal pathway, and where the patient is.
Yes. Physician assistants can prescribe peptides in all 50 states and DC, because a peptide used as a drug falls under the same prescriptive authority that lets a PA prescribe any other prescription drug, and no state requires a separate peptide license or certification.
Whether a particular PA can prescribe a particular peptide to a particular patient is a narrower question. Four checks decide it: what relationship with a physician the state requires, what the PA's practice agreement or formulary covers, whether the product itself has a lawful pathway, and which state the patient is located in. This guide takes each in turn, then covers what to write into a practice agreement before the first peptide prescription and where PAs can get trained in peptide therapy.
Status as of October 26, 2026. State classifications follow the American Academy of Physician Associates' PA practice modernization tracker. For physicians, NPs, and other licenses side by side, see our guide to who can prescribe peptides.
| Check | Where the answer lives | How it fails |
|---|---|---|
| Physician relationship | State PA practice act and medical or PA board rules | The PA has not met the experience threshold for practice without a specific physician, or the setting is excluded |
| Agreement or formulary | The practice agreement, prescriptive authority agreement, or board formulary | The agreement lists drug categories that leave out compounded injectables or peptide therapy |
| Product | FDA approval, or the federal compounding rules | The product is a research use only peptide, or a compound whose bulk substance does not qualify |
| Patient location | The licensing rules of the state where the patient sits | The PA treats a patient in a state where the PA holds no license, often by telehealth |
A PA who clears all four can prescribe the peptide. Failing any one leaves the PA without authority, however strong the PA's training.
Most states still tie PA practice to a specific physician, through supervision or a collaboration agreement. AAPA counts ten states that have removed the legal requirement for a relationship with a specific physician: Delaware, Iowa, Maine, Montana, New Hampshire, North Dakota, South Dakota, Utah, Virginia, and Wyoming. Most of them attach conditions, usually a minimum number of practice hours, and some are still being implemented. Delaware's pathway, for example, does not operate until its regulations are approved or May 12, 2027, whichever comes first. A PA in one of these states should confirm that they personally qualify before treating the agreement as optional.
Peptides rarely touch the controlled substance limits that dominate PA scope debates. Most therapeutic peptides are not scheduled under the federal Controlled Substances Act, so Schedule II restrictions and DEA registration do not usually apply to them. The question that matters for peptides is what the physician relationship says.
Wherever the state requires a physician relationship, the document behind it decides the peptide question. A prescription the agreement does not cover is one the PA has no authority to write, even in a state that lets PAs prescribe peptides in general. Three states show how differently that document works.
Texas. PAs prescribe under a prescriptive authority agreement, and Tex. Occ. Code 157.0512 requires it to "identify the types or categories of drugs or devices that may be prescribed or the types or categories of drugs or devices that may not be prescribed." The same section requires chart review and documented meetings with the physician at least once a month. An agreement written for an urgent care or primary care practice may not reach compounded injectables. Our Texas guide covers the delegation and med spa rules that sit on top of it.
California. A PA furnishes or orders drugs under a practice agreement that, under Bus. & Prof. Code 3502.1, must specify "which drugs or devices may be furnished or ordered, under what circumstances," and the extent of supervision. The physician does not have to be on site but must be reachable by phone or electronically when the PA examines the patient. Peptides have to fall within that list. Our California guide covers the state's good-faith exam rule and pharmacy law.
Alabama. A PA may prescribe a legend drug only when its type, dosage, quantity, and refills are authorized in a job description signed by the supervising physician and approved by the Board of Medical Examiners, and the drug is on the board's PA formulary (Ala. Admin. Code 540-X-7-.28). Controlled substances are limited to Schedules III through V and need a separate state certificate. An Alabama PA should get the peptide written into the approved job description before the first prescription.
Prescriptive authority only reaches products with a lawful pathway into patient care. For peptides there are two.
FDA-approved peptide drugs. A PA may prescribe an approved peptide drug for its labeled indication, and off label where state law and the agreement allow it.
Compounded peptides. A 503A pharmacy may compound a drug on the prescription of "a licensed physician or other licensed practitioner authorized by State law to prescribe drugs" (21 U.S.C. 353a). That language includes PAs with prescriptive authority. The bulk substance still has to qualify, which is a moving target; our map of the FDA compounding categories tracks it.
Research use only peptides have no pathway at all. The Alabama Board of Medical Examiners issued an official notice naming PAs directly: "no CNM, CRNP, or PA is legally authorized to prescribe, administer, advise, or dispense a non-FDA-approved or research grade peptide." It adds that consent forms labeling a product "research-grade" do not reduce the clinician's liability. Our guide to research use only peptides explains why those products are not a prescribing pathway.
Growth hormone is the one peptide hormone with a federal rule written around physicians. Under 21 U.S.C. 333(e), distributing human growth hormone is a felony unless it is for an FDA-authorized condition and "pursuant to the order of a physician." A PA who prescribes somatropin, even for an approved indication, should get a legal opinion on how that language applies first. Growth hormone secretagogues are separate drugs and fall outside the statute.
A PA needs a PA license in the state where the patient is located at the time of care, including for a telehealth visit. The PA Licensure Compact will eventually ease this, but not yet. As of August 28, 2026 it had 29 member states and no state was issuing privileges; the compact commission projects the first privileges in early 2027. Even then, a PA applies for a separate privilege in each state and follows that state's scope and any agreement it requires. Until then, a PA running a multistate telehealth peptide program needs a separate license for each state served, and a separate agreement wherever the state requires one.
A PA adding peptides should amend the agreement before the first prescription, not after. These are the provisions that matter.
| Provision | What it should say |
|---|---|
| Drug categories | Names compounded injectable peptides and the approved peptide drugs the PA will prescribe, not just "prescription drugs" |
| Off-label use | States whether off-label prescribing is authorized and what documentation it requires |
| Sourcing | Limits orders to licensed 503A pharmacies or registered 503B outsourcing facilities, and rules out research use only suppliers |
| Evaluation and consent | Requires a documented exam, indication, and informed consent covering regulatory status and evidence |
| Monitoring | Sets baseline and follow-up labs by therapy class, and when the PA consults the physician |
| Chart review | Sets how many peptide charts the physician reviews and how often, which Texas requires in writing |
Physicians who sign these agreements carry their own exposure. The Alabama notice says a physician "may not circumvent his or her duty of care to patients by permitting or delegating the purchase, administration, or dispensing" of research grade peptides to a PA. A specific agreement protects both clinicians.
No. Authority comes from the PA license and, where the state requires one, the agreement. A certification gives a licensed PA the clinical and regulatory knowledge to prescribe peptides to the standard of care: indications, dosing, contraindications, monitoring, sourcing, and documentation. Boards judge prescriptions against that standard, and in most states the supervising or collaborating physician reviews them too, so documented, accredited training supports the PA's position and makes the agreement amendment easier to get signed.
Pick training that counts toward certification maintenance. NCCPA requires 100 CME credits every two years, at least 50 of them Category 1, and it accepts both AAPA Category 1 CME and AMA PRA Category 1 Credit from ACCME-accredited providers. A peptide "certificate" with no Category 1 designation adds nothing to that total. Beyond the credit, look for a course that covers the compounding rules and research use only products, not only dosing, and that gives you written protocols your physician can review.
Our peptide course for physician assistants is designated for 20 AAPA Category 1 CME credits, taught by a prescribing physician, with protocols, consent templates, and eight patient cases built to bring to a collaborating physician. For other programs side by side, see our comparison of peptide certification courses.
In the ten states AAPA lists as having removed the specific-physician requirement, a PA who meets the state's conditions can. Everywhere else, PAs prescribe peptides under supervision or a collaboration agreement with a physician, and that document has to cover them.
Yes. Federal law lets a 503A pharmacy compound on the prescription of any practitioner authorized by state law to prescribe, which includes PAs. The bulk substance has to qualify under the FDA compounding rules, and the PA's agreement or formulary has to allow it.
No. Research use only peptides are not lawful prescription drugs in any state. Alabama's medical board has said directly that no PA is authorized to prescribe, administer, or even advise on them, and that a patient consent form does not change that.
Usually not for the peptide itself, because most therapeutic peptides are not federally controlled substances. A PA needs DEA registration, and in some states a state certificate, for any scheduled drug in the same program, such as testosterone, which is Schedule III.
Only with a PA license in the patient's state. The PA Licensure Compact has not started issuing privileges and expects to in early 2027.
Yes, when it carries AAPA Category 1 CME or AMA PRA Category 1 Credit from an ACCME-accredited provider. It counts toward the 50 Category 1 credits each two-year cycle requires.